These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16342922)

  • 21. Bayesian approaches in medical device clinical trials: a discussion with examples in the regulatory setting.
    Bonangelino P; Irony T; Liang S; Li X; Mukhi V; Ruan S; Xu Y; Yang X; Wang C
    J Biopharm Stat; 2011 Sep; 21(5):938-53. PubMed ID: 21830924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian hierarchical modeling for detecting safety signals in clinical trials.
    Xia HA; Ma H; Carlin BP
    J Biopharm Stat; 2011 Sep; 21(5):1006-29. PubMed ID: 21830928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making what's advanced today routine tomorrow.
    Ruberg SJ
    J Biopharm Stat; 2016; 26(1):55-70. PubMed ID: 26397979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perspectives on the use of adaptive designs in clinical trials. Part I. Statistical considerations and issues.
    Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1090-7. PubMed ID: 21058104
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.
    Segreti AC; Leung HM; Koch GG; Davis RL; Mohberg NR; Peace KE
    J Biopharm Stat; 2001 Nov; 11(4):347-72. PubMed ID: 12018784
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Guest editors' note: Bayesian approaches for medical product evaluation--today and tomorrow.
    Li X; Xu Y
    J Biopharm Stat; 2011 Sep; 21(5):869-70. PubMed ID: 21830919
    [No Abstract]   [Full Text] [Related]  

  • 29. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bayesian adaptive clinical trials: a dream for statisticians only?
    Chevret S
    Stat Med; 2012 May; 31(11-12):1002-13. PubMed ID: 21905067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Bayesian methods make data and analyses more relevant to decision makers? A perspective from Medicare.
    Sheingold SH
    Int J Technol Assess Health Care; 2001; 17(1):114-22. PubMed ID: 11329838
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Translational medicine].
    Antal J; Timár A
    Orv Hetil; 2011 Nov; 152(47):1894-902. PubMed ID: 22042316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Selection of licensing candidates in the pharmaceutical industry: an application of the analytic hierarchy process.
    Ross ME; Nydick RL
    J Health Care Mark; 1992 Jun; 12(2):60-5. PubMed ID: 10119215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Barriers and opportunities for implementation of adaptive designs in pharmaceutical product development.
    Quinlan J; Gaydos B; Maca J; Krams M
    Clin Trials; 2010 Apr; 7(2):167-73. PubMed ID: 20338900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Aiming for zero blindness].
    Nakazawa T
    Nippon Ganka Gakkai Zasshi; 2015 Mar; 119(3):168-93; discussion 194. PubMed ID: 25854109
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology.
    Brannath W; Zuber E; Branson M; Bretz F; Gallo P; Posch M; Racine-Poon A
    Stat Med; 2009 May; 28(10):1445-63. PubMed ID: 19266565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paradigms for adaptive statistical information designs: practical experiences and strategies.
    Wang SJ; Hung HM; O'Neill R
    Stat Med; 2012 Nov; 31(25):3011-23. PubMed ID: 22927234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.
    Krams M; Burman CF; Dragalin V; Gaydos B; Grieve AP; Pinheiro J; Maurer W; Gallo P
    J Biopharm Stat; 2007; 17(6):957-64. PubMed ID: 18027207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paving the critical path: how can clinical pharmacology help achieve the vision?
    Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):170-7. PubMed ID: 17259944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Professional development of statisticians in the pharmaceutical sector: evolution over the past decade and into the future.
    Lewis T
    Pharm Stat; 2008; 7(3):158-69. PubMed ID: 18720452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.